

9 October 2020



CLINUVEL PHARMACEUTICALS LTD 2020 Annual General Meeting

Dear Shareholder,

CLINUVEL PHARMACEUTICALS LTD's 2020 Annual General Meeting (AGM) will be held on Wednesday, 11 November 2020 at 06.00pm (Melbourne time). To comply with COVID19 requirements set out in Government restrictions on travel and public gatherings, the AGM will be held as a virtual meeting. The Company will rely on technology to facilitate shareholder engagement during the meeting.

Temporary modifications to the *Corporations Act 2001* allow the Company not to despatch physical copies of the Notice of 2020 AGM and Explanatory Memorandum. Instead these materials will be made available to shareholders electronically. The Notice of 2020 AGM is available on our website at www.clinuvel.com/investors, or at the Company's share registry's online voting site, InvestorVote, at www.investorvote.com.au/302464225.

Shareholders will also find instructions for how to join and view the meeting online, submit questions and cast your vote during the meeting at www.clinuvel.com/investors and in the Notice of AGM and Explanatory Memorandum 2020.

To participate online live on the day of the meeting, you will need to go to: <https://web.lumiagm.com/302464225>. Any holders wishing to lodge a proxy vote or lodge questions ahead of the meeting can do this by logging onto www.investorvote.com.au and entering the Control Number and your holder number (SRN/HIN) located on their Proxy Form. Lodging questions or casting your proxy vote ahead of the meeting will not prevent you from attending online. The Company recommends shareholders lodge a directed proxy as soon as possible in advance of the AGM even if they plan to attend online.

The business of the meeting set out in the Notice of 2020 AGM and accompanying Explanatory Memorandum is to:

1. consider the statutory reports for the financial year ended 30 June 2020;
2. adopt the 2020 Remuneration Report;
3. re-elect Willem Blijdorp as non-executive director; and
4. re-elect Jeffrey Rosenfeld as non-executive director.

Each director (where permitted to do so) recommends that shareholders vote in favour of each of the above items of business.

If it becomes necessary or appropriate to make alternative arrangements regarding the 2020 AGM, the Company will make further information available through the ASX website at www.asx.com.au (ASX:CUV) and on its website at www.clinuvel.com/investors.

I hope you can take advantage of the new technology we are using this year to hold the Company's AGM.

Yours faithfully,

Willem Blijdorp

Chair

CLINUVEL PHARMACEUTICALS LTD

THIS IS AN IMPORTANT DOCUMENT AND REQUIRES YOUR ATTENTION

If you are in doubt as to how to deal with it, please consult your financial or other professional adviser

CLINUVEL PHARMACEUTICALS LIMITED

ACN 089 644 119

NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM 2020

DATE:

WEDNESDAY, 11 NOVEMBER 2020

TIME:

6.00pm (Melbourne time)

PLACE:

Virtual meeting through Lumi



CLINUVEL

Notice of Annual General Meeting

CLINUVEL PHARMACEUTICALS LIMITED ACN 089 644 119

Notice is given that the Annual General Meeting of CLINUVEL PHARMACEUTICALS LIMITED ACN 089 644 119 (**Company**) will be held at:

Location	Via webcast at https://web.lumiagm.com/302464225
Date	Wednesday 11 November 2020
Time	06.00pm (Melbourne time)

The Explanatory Memorandum provides additional information on matters to be considered at the Meeting. The Explanatory Memorandum and Proxy Form are part of this Notice.

Terms used in this Notice will, unless the context requires otherwise, have the same meaning given to them in the glossary contained in the Explanatory Memorandum.

ORDINARY BUSINESS

Receipt of the Financial Statements and Reports

To receive and consider the Financial Statements of the Company for the year ended 30 June 2020, together with the Directors' Report and the Independent Auditor's Report as set out in the Annual Report.

Resolution 1 – Adoption of Remuneration Report

To consider, and if in favour, to pass the following resolution as **an ordinary resolution**:

'That, in accordance with Section 250R of the Corporations Act, the Remuneration Report as set out in the Directors' Report for the year ended 30 June 2020 be adopted.'

Resolution 2 – Re-election of Mr Willem Blijdorp

To consider, and if in favour, to pass the following resolution as **an ordinary resolution**:

'That Mr Willem Blijdorp, a Director retiring by rotation in accordance with clause 57 of the Constitution of the Company and the ASX Listing Rules, being eligible and having offered himself for re-election, be re-elected as a Director.'

Resolution 3 – Re-election of Prof Jeffrey Rosenfeld

To consider, and if in favour, to pass the following resolution as **an ordinary resolution**:

'That Prof Jeffrey Rosenfeld, a Director retiring by rotation in accordance with clause 55 of the Constitution of the Company and the ASX Listing Rules, being eligible and having offered himself for re-election, be re-elected as a Director.'

Voting Exclusion Statement

In accordance with ASX Listing Rule 14.11, the Company will disregard any votes cast on the respective resolutions by the following persons:

Resolution	Exclusion
1 - Adoption of Remuneration Report	<p>The Company will disregard any votes cast on Resolution 1 by or on behalf of any member of the Key Management Personnel whose remuneration is included in the Remuneration Report or any Closely Related Party of such person.</p> <p>In accordance with section 250BD of the Corporations Act, a vote on Resolution 1 must not be cast by or on behalf of a person appointed (including as a proxy), where that person is either a member of the Key Management Personnel or a Closely Related Party of such person whose remuneration is included in the Remuneration Report.</p> <p>A vote may be cast by such person if:</p> <ul style="list-style-type: none">(a) the vote is not cast on behalf of a person who is otherwise excluded from voting and the appointment specifies how the proxy is to vote; or(b) the person appointed as proxy is the Chairman and the appointment does not specify how the Chairman is to vote but expressly authorises the Chairman to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.
2 - Re-election of Mr Willem Blijdorp	No voting restrictions are applicable to this Resolution 2 (however Mr Willem Blijdorp will abstain from voting).
3 - Re-election of Prof Jeffrey Rosenfeld	No voting restrictions are applicable to this Resolution 3 (however Prof Jeffrey Rosenfeld will abstain from voting).

Dated 09 October 2020

By order of the Board

Darren Keamy
Company Secretary

Notes

How to Participate and Vote at the Virtual Meeting

It is recommended Shareholders log into the webcast at least 15 minutes prior to the scheduled start time of the Meeting. To participate in the virtual Meeting, you can log into the Meeting via the following ways:

- 1) From your computer, by entering the URL in your browser <https://web.lumiagm.com/302464225>;
or
- 2) From your mobile device, by entering the URL in your browser <https://web.lumiagm.com/302464225> or by downloading the Lumi AGM app from the Apple App or Google Play stores by searching for the Lumi AGM app;

Once one of the options above has been selected, Shareholders will need the following information to participate in the Meeting:

- 1) Your User Name, which is your SRN/HIN number; and
- 2) Your password, which is the postcode registered to your holding if you are an Australian Shareholder. Overseas shareholders should refer to the Online Meeting Guide, found in www.clinuvel.com/investors, for their password details

Shareholders can submit questions in relation to the business of the meeting and vote on the resolutions during the course of the Meeting via the Lumi AGM online platform. Shareholders can vote between the commencement of the meeting and until such time the Chair of the Meeting announces voting is closed.

By participating in the Meeting online you will be able to hear and view presentations, submit written questions whilst the Meeting is in progress and vote during the Meeting.

Instructions on how to log on and ask questions during the Meeting are outlined below and can also be found on the Company's website at www.clinuvel.com/investors

Please note, only Shareholders may ask questions online and only once they have been verified. It may not be possible to respond to all questions raised during the Meeting. The Company recommends Shareholders lodge questions prior to the Meeting. Questions can be submitted via www.investorvote.com.au. You will require your SRN/HIN and the control number (printed on your proxy form). Alternatively you can log onto www.clinuvel.com/investors and download the shareholder question form.

In the Meeting the Company may respond to written questions received prior to the Meeting thematically. The Company will not respond or answer to questions which it views to be defamatory, vexatious, would result in confidential or commercially sensitive information to be released to the Company's detriment or if the Company believes the questions are not posed by Shareholders in their capacity as Shareholders.

Appointing a Proxy and voting online before the Meeting

If you wish to appoint a proxy and are entitled to do so, then complete and return the attached Proxy Form to Computershare Investor Services Pty Limited, GPO Box 242 Melbourne, Victoria 3001 Australia or alternatively by fax to 1800 783 447 (within Australia) or +61 3 9473 2555 (outside Australia) by 10am (Melbourne time) Monday, 09 November 2020, being at least 48 hours before the holding of the Annual General Meeting.

Online voting prior to the Meeting will be available at www.investorvote.com.au. You will require your SRN/HIN and the control number (printed on your proxy form).

For Intermediary Online subscribers only (custodians) please visit www.intermediaryonline.com to submit your voting intentions.

A Shareholder who is entitled to attend and cast a vote at the Meeting is entitled to appoint a proxy. The proxy need not be a Shareholder. It is recommended for Shareholders to notify an appointed proxy of their appointment to enable them to participate in the meeting online and to exercise their voting instructions. Appointed proxies

will need to contact the Company's share registry, Computershare Investor Services Pty Ltd, to obtain a username and password to vote online.

A Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise.

If you appoint a proxy, it is recommended to direct your proxy how to vote on each item by marking the appropriate boxes on the proxy form. If you do not specify a proxy in your completed proxy vote or if the person you appoint does not participate in the Meeting, the Chair of the Meeting will be taken to be your proxy by default. Any directed proxies that are not voted as directed on a poll at the meeting will automatically default to the Chair of the Meeting, who is required to vote proxies as directed.

Corporate Representative

A corporation may elect to appoint a representative, rather than appoint a proxy, under the Corporations Act in which case the Company will require written proof of the representative's appointment which must be lodged with the Company or its share registry, Computershare Investor Services Pty Limited, in advance of the Meeting or handed in at the Meeting when registering as a Corporate Representative.

Eligibility to Vote and Attend the Meeting

The Company has determined under regulation 7.11.37 Corporations Regulations 2001 (Cth) that for the purpose of voting at the Meeting or adjourned meeting, Shares are taken to be held by those persons recorded in the Company's register of Shareholders as at 7.00pm (Melbourne time) on Monday, 09 November 2020.

The Annual General Meeting is a private meeting for shareholders. Only members of the Company and/or their proxies and Company invited guests are entitled to attend.

Technical Difficulties

Technical difficulties may arise during the course of the Meeting. The Chair of the Meeting has discretion as to whether and how the Meeting should proceed in the event a technical difficulty arises. In exercising discretion, the Chair of the Meeting will have regard to the number of Shareholders impacted and the extent to which participation in the business of the Meeting is affected. Where considered appropriate, the Chair of the Meeting may continue to hold the Meeting and transact business, including conducting a poll and voting in accordance with valid proxy instructions. For this reason, it is recommended holders lodge a directed proxy no later than 48 hours before the holding of the Meeting. However if you do attend the Meeting via the Lumi online platform you will be taken as being present at the Meeting and will have to vote through that platform even if you have appointed a proxy.

Poll

The Chair of the Meeting intends to call a poll on each of the Resolutions set out in this Notice of Meeting. The results of the voting on resolutions requiring a shareholder vote at the Meeting will be announced to the ASX promptly after the Meeting.

If you have any queries on how to cast your votes call Darren Keamy on (03) 9660 4900 during business hours.

Explanatory memorandum

CLINUVEL PHARMACEUTICALS LIMITED ACN 089 644 119 (**Company**)

This Explanatory Memorandum has been prepared for the Shareholders of the CLINUVEL PHARMACEUTICALS LIMITED ACN 089 644 119 in connection with the business to be conducted at the Annual General Meeting of Shareholders of the Company which will be held at:

Location	Via webcast at https://web.lumiagm.com/302464225
Date	Wednesday 11 November 2020
Time	06.00pm (Melbourne time)

This Explanatory Memorandum should be read in conjunction with, and form part of, the accompanying Notice. The Directors recommend that Shareholders read this Explanatory Memorandum in full before making any decision in relation to the Resolutions.

Terms used in this Explanatory Memorandum will, unless the context requires otherwise, have the same meaning given to them in the glossary as contained in this Explanatory Memorandum.

ORDINARY BUSINESS

RECEIPT OF THE FINANCIAL STATEMENTS AND REPORTS

Pursuant to section 317 of the Corporations Act, the Company is required to lay before the meeting the financial report and the reports of the Directors and the auditor to give Shareholders a reasonable opportunity to ask questions or make comment. There is no requirement for Shareholders to approve these reports (other than the non-binding vote in respect of the Remuneration Report forming part of the Directors' Report – see Resolution 1).

Resolution 1 - Adoption of the remuneration report

The Remuneration Report is set out in the Directors' Report of the Company's Annual Report for the year ended 30 June 2020. The Remuneration Report sets out the policy for the remuneration of the Directors and executives.

The Corporations Act requires the Remuneration Report be put to a non-binding vote of the Shareholders. The vote is advisory only and does not bind the Directors or the Company. However if 25% or more of votes that are cast are voted against the adoption of the Remuneration Report at two consecutive AGMs, Shareholders will be required to vote at the second of the AGMs on a "spill resolution" that another meeting be held within 90 days at which all the Company's Directors (other than the Managing Director) must be presented for re-election.

There is no requirement to allow for a possible 'spill' resolution at this Meeting as the 2019 Remuneration Report was accepted by greater than 75% of shares voted in the 2019 Annual General Meeting.

The Directors will consider the outcome of the vote on the Remuneration Report when reviewing the Company's remuneration policies.

Recommendation

The Directors recommend Shareholders vote in favour of Resolution 1.

Resolution 2 - Re-election of Mr Willem Blijdorp

Under clause 57 of the Constitution, at each Annual General Meeting, one third of the Directors (or, if their number is not a multiple of three, then the number nearest to but not exceeding one third) must retire from office.

The Directors retire by rotation, with the Directors who have been the longest in office since being elected or re-elected being the Directors who must resign in any year. The Constitution ensures that no Director is able to

remain in office for longer than three years without facing re-election. Under the Constitution and the ASX Listing Rules, the Managing Director is exempt from the requirement to retire by rotation (i.e. Dr Wolgen).

To comply with the requirements of clause 57 of the Constitution, Mr Willem Blijdorp must retire at the Meeting. Mr Blijdorp wishes to continue as a Director and is entitled under the Constitution to seek re-election as a Director at the Meeting which coincides with his retirement, and accordingly offers himself for re-election as a Director.

Biographical Details

Mr Blijdorp is an internationally recognised entrepreneur who has helped built the B&S Group, one of the largest global trading houses, in a period spanning three decades. Mr Blijdorp has led B&S's growth, with the Dutch group focused on the specialty distribution services to difficult to serve markets. The B&S Group has global reach and is a leader in its market sector.

Formerly B&S Group's CEO, Mr Blijdorp now serves on its Supervisory Board and is a majority shareholder, focusing on the Group's development and expansion strategy. He led and oversaw the Group's initial public offering on Euronext Amsterdam in March 2018. In 2014 Mr Blijdorp was recognised for his expertise in merger and acquisitions and commercial leadership as the Ernst & Young Entrepreneur of the Year in the Netherlands, and runner-up in its European Union awards.

Since becoming a director of CLINUVEL in 2015, Mr Blijdorp has provided a valuable contribution to setting the Group's long-term strategy for product commercialisation, growth, and future plans to further diversify CLINUVEL.

Recommendation

The Directors, other than Mr Blijdorp, recommend Shareholders vote in favour of Resolution 2.

Resolution 3 – Re-election of Prof Jeffrey Rosenfeld

Under clause 55 of the Constitution, a Director appointed to fill casual vacancy holds office until the end of the next Annual General Meeting of the Company, at which the Director may be re-elected. Prof Rosenfeld was appointed, after appropriate background checking, to fill a casual position after the 2019 Annual General Meeting and therefore must retire at the Annual General Meeting. Prof Rosenfeld wishes to continue as a Director, and as he is entitled under the Constitution to seek re-election as a Director at the Annual General Meeting which coincides with his retirement, offers himself for re-election as a Director.

Biographical Details

Prof Rosenfeld is an internationally recognised neurosurgeon with extensive experience in senior healthcare and medical research executive roles and a distinguished and decorated career in the Australian Army. He is a retired Major General and a former Surgeon General, Australian Defence Force-Reserves. He has served on eight deployments to Rwanda, Iraq, Solomon Islands, Bougainville and East Timor. He was the Founding Director of Monash University Institute of Medical Engineering (MIME)-Melbourne. He is developing a bionic vision device to restore vision in blind people and he is also a leader in brain injury research. Prof Rosenfeld was Director of Neurosurgery at the Alfred Hospital for fifteen years, concurrently holding Professor and Head of the Department of Surgery at Monash University for nine years. Prof Rosenfeld is active in many community organisations and champions various charitable causes. Prof Rosenfeld is an active volunteer the Australian-Aid funded Pacific Islands Project which transfers clinical skills and knowledge to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands.

In 2018, Prof Rosenfeld was awarded the Companion of the Order of Australia, which is Australia's highest civilian honour, the Meritorious Service Medal of the United States of America in 2017 and Officer in the Order of the British Empire in 2013.

Recommendation

The Directors, other than Prof Rosenfeld, recommends Shareholders vote in favour of Resolution 3.

Glossary

1. Definitions

“**Annual Report**” means the annual report of the Company for the year ended 30 June 2020.

“**ASX**” means ASX Limited.

“**ASX Listing Rules**” means the official listing rules and requirements from time to time of the ASX.

“**Board**” means the board of Directors of the Company as constituted from time to time.

“**Chairman**” or “**Chair**” means the person appointed to chair the Meeting convened by the Notice.

“**Closely Related Party**” has the meaning given in section 9 of the Corporations Act.

“**Company**” or “**CLINUVEL**” means CLINUVEL PHARMACEUTICALS LIMITED ACN 089 644 119.

“**Constitution**” means the constitution of the Company.

“**Corporations Act**” means the *Corporations Act 2001* (Cth).

“**Directors**” means the directors of the Company from time to time.

“**Explanatory Memorandum**” means the explanatory memorandum which forms part of the Notice.

“**Key Management Personnel**” means a person having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company.

“**Meeting**” means the Annual General Meeting of Shareholders of the Company convened by the Notice, to be held as a Virtual meeting through Lumi on 11 November 2020 at 06pm Australian Eastern Daylight (AEDT) time.

“**Notice**” means this notice of meeting which comprises of the notice, Explanatory Memorandum and Proxy Form

“**Proxy Form**” means the proxy form attached to the Notice.

“**Resolution**” means a resolution contained in this Notice.

“**Share**” means a fully paid ordinary share in the capital of the Company

“**Shareholder**” or “**Member**” means a registered holder of a Share.


2. Interpretation


- (a) The singular includes the plural and vice versa and words denoting any gender include all genders;
- (b) A reference to “\$”, “A\$” or “dollar” is a reference to Australian currency; and
- (c) A reference to a time is a reference to Australian Eastern Standard Time or Australian Eastern Daylight Time, whichever is appropriate.

CUVRM

MR RETURN SAMPLE
123 SAMPLE STREET
SAMPLE SUBURB
SAMPLETOWN VIC 3030

Need assistance?

 **Phone:**
1300 850 505 (within Australia)
+61 3 9415 4000 (outside Australia)

 **Online:**
www.investorcentre.com/contact



YOUR VOTE IS IMPORTANT

For your proxy appointment to be effective it must be received by **6.00pm (Melbourne time) on Monday, 9 November 2020.**

Proxy Form

How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

APPOINTMENT OF PROXY

Voting 100% of your holding: Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

Voting a portion of your holding: Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

Appointing a second proxy: You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

SIGNING INSTRUCTIONS FOR POSTAL FORMS

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

PARTICIPATING IN THE MEETING

Corporate Representative

If a representative of a corporate securityholder or proxy is to participate in the meeting you will need to provide the appropriate "Appointment of Corporate Representative". A form may be obtained from Computershare or online at www.investorcentre.com under the help tab, "Printable Forms".

Lodge your Proxy Form:

XX

Online:

Lodge your vote online at www.investorvote.com.au using your secure access information or use your mobile device to scan the personalised QR code.

Your secure access information is



Control Number: 999999

PIN: 99999

For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com

By Mail:

Computershare Investor Services Pty Limited
GPO Box 242
Melbourne VIC 3001
Australia

By Fax:

1800 783 447 within Australia or
+61 3 9473 2555 outside Australia



PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

Change of address. If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with 'X') should advise your broker of any changes.



I N D

Proxy Form

Please mark to indicate your directions

Step 1 Appoint a Proxy to Vote on Your Behalf

XX

I/We being a member/s of Clinuvel Pharmaceuticals Limited hereby appoint

the Chairman of the Meeting **OR**

PLEASE NOTE: Leave this box blank if you have selected the Chairman of the Meeting. Do not insert your own name(s).

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairman of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the Annual General Meeting of Clinuvel Pharmaceuticals Limited to be held online on Wednesday, 11 November 2020 at 6.00pm (Melbourne time) and at any adjournment or postponement of that meeting.

Chairman authorised to exercise undirected proxies on remuneration related resolutions: Where I/we have appointed the Chairman of the Meeting as my/our proxy (or the Chairman becomes my/our proxy by default), I/we expressly authorise the Chairman to exercise my/our proxy on Resolution 1 (except where I/we have indicated a different voting intention in step 2) even though Resolution 1 is connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chairman.

Important Note: If the Chairman of the Meeting is (or becomes) your proxy you can direct the Chairman to vote for or against or abstain from voting on Resolution 1 by marking the appropriate box in step 2.

Step 2 Items of Business

PLEASE NOTE: If you mark the **Abstain** box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

		For	Against	Abstain
Resolution 1	Adoption of the Remuneration Report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 2	Re-election of Mr Willem Blijdorp	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 3	Re-election of Prof Jeffrey Rosenfeld	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business. In exceptional circumstances, the Chairman of the Meeting may change his/her voting intention on any resolution, in which case an ASX announcement will be made.

Step 3 Signature of Securityholder(s) *This section must be completed.*

Individual or Securityholder 1 Securityholder 2 Securityholder 3 / /
Sole Director & Sole Company Secretary Director Director/Company Secretary Date

Update your communication details (Optional)

Mobile Number Email Address By providing your email address, you consent to receive future Notice of Meeting & Proxy communications electronically

